Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: A phase II clinical study

Tumori

Volumn 87, Issue 3, 2001, Pages 120-126

  Deraco, M ^a   Rossi, C R ^a   Pennacchioli, E ^a   Guadagni, S ^a   Somers, D C ^a   Santoro, N ^a   Raspagliesi, F ^a   Kusamura, S ^a   Vaglini, M ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cytoreductive surgery; Intraperitoneal hyperthermic perfusion; Ovarian cancer; Peritoneal carcinomatosis

Indexed keywords

CISPLATIN; MITOMYCIN C; PACLITAXEL;

ABDOMINAL BLEEDING; ADULT; AGE; AGED; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER STAGING; CANCER SURGERY; CARCINOMATOUS PERITONITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; FOLLOW UP; HEMATURIA; HUMAN; HYPERTHERMIC THERAPY; MINIMAL RESIDUAL DISEASE; NEPHROTOXICITY; OVARY CANCER; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; RECURRENT CANCER; SALVAGE THERAPY; SURVIVAL RATE;

EID: 0034935417     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160108700302     Document Type: Article

References (55)

1. Ovarian cancer: Age contrasts in incidence, histology, disease stage at diagnosis, and mortality
2. The natural history and treatment of ovarian cancer
3. Peritoneal carci-nomatosis: Features of dissemination
4. Intraperitoneal cisplatin and carboplatin in the management of ovarian cancer
5. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis form gastrointestinal cancer: Pharmacological studies
6. Phase III study of intraperitoneal (IP) cisplatin (CDDP)/intravenous (IV) cyclophosphamide (CPA) in patients with optimal disease stage III ovarian cancer: A AWOG-GOG-ECOG intergroup study
7. Intraperitoneal cisplatin based chemotherapy for ovarian carcinoma
8. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy
9. Intraperitoneal chemotherapy
10. Hyperthermia and drugs
11. Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin C toward hypoxic tumor cells
12. Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumor cells
13. Intraperitoneal hyperthermic chemotherapy in gastric cancer: Rationale for a new approach
14. Clinical pathway for peritoneal carcinomatosis from colon and rectal cancer: Guidelines for current practice
15. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with MMC
16. Hyperthermia-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination
17. Intraperitoneal hyperthermic perfusion (IPHP): Analysis of morbidity and toxicity
18. Diffuse and gross peritoneal carcinomatosis treated by intraperitoneal hyperthermic chemoperfusion
19. Intraperitoneal chemo-hyperthermia in the treatment of peritoneal carcinomatosis of ovarian origin. Initial cases, physiopathologic data
20. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer
21. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines
22. The general rules for the gastric cancer study in surgery and pathology
23. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis
24. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer
25. Ovarian cancer
26. Second look laparotomy in managing epithelial ovarian carcinoma
27. Adriamycin and cisplatinum in advanced ovarian cancer
28. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma
29. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma
30. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: Alternating sequences of combination regimens
31. Multimodal approach (surgery, chemotherapy and radiotherapy) in the treatment of advanced ovarian carcinoma
32. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclosphosphamide in stage III-IV epithelial ovarian carcinoma
33. Survival after second-look laparotomy in advanced ovarian epithelial cancer. Study of 86 patients
34. Prognosis of surgically determined complete responders in advanced ovarian cancer
35. Complete remission at laparotomy: Still a gold standard in ovarian cancer?
36. A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma: A Gynecologic Oncology Group study
37. Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: A pilot study
38. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: Influence of a prior response to intravenous cisplatin
39. Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian
40. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: A multivariate analysis of survival for 100 consecutively treated patients
41. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
42. Paclitaxel for platinum refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute Referral center 9103
43. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer
44. Survival of patients following secondary cytoreductive surgery in ovarian cancer
45. Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study
46. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer
47. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer
48. Secondary cytoreduction for ovarian cancer following cisplatin therapy
49. Cytoreductive surgery in ovarian carcinoma patients with documented previously complete surgical response
50. A mathematics model for relating the drug sensitivity of tumors to their spontaneous mutation rate
51. Peritoneal-plasma barrier
52. Razionale per un trattamento chemioipertermico della carcinosi peritoneale